On December 9, 2024, Brett Sandercock, the Chief Financial Officer of ResMed Inc's subsidiary, sold 1,000 shares of ResMed Inc (RMD, Financial). Following this transaction, the insider now owns 93,864 shares of the company. The details of this transaction can be found in the SEC Filing.
ResMed Inc is a global leader in the development, manufacturing, and distribution of medical equipment for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company provides innovative solutions to improve the quality of life for patients and reduce the impact of chronic diseases.
Over the past year, Brett Sandercock has sold a total of 20,000 shares and has not made any purchases. The insider transaction history for ResMed Inc indicates that there have been no insider buys in the past year, while there have been 35 insider sells.
On the day of the recent sale, shares of ResMed Inc were trading at $244.23, giving the stock a market cap of $35.877 billion. The company's price-earnings ratio stands at 32.37, which is higher than the industry median of 29.575 but lower than the company's historical median price-earnings ratio.
With a trading price of $244.23 and a GuruFocus Value of $270.58, ResMed Inc has a price-to-GF-Value ratio of 0.9, indicating that the stock is modestly undervalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
